Please note that this is an English translation of a press release written in Swedish by Ortoma AB (publ), in the event of any inaccuracies, the Swedish version applies. The information was submitted for publication 2024-11-15.
Linus Byström leaves the CEO position in Ortoma AB
Ortoma’s CEO Linus Byström is leaving the company today after creditably leading the company in his role as CEO since 2017. The board has appointed Anders Hahn as acting CEO until a successor has been appointed.
Anders Hahn has been a board member in Ortoma AB since the general meeting in May 2024. He has 30 years of experience from the MedTech industry and above all in orthopedics, Ortoma’s customer segment. Previous positions include roles as Country Manager and Sales Director for Zimmer Biomet, CEO and Business Unit Manager for Biomet Ortopaedics AB. Furthermore, Anders has worked at companies such as Anatomica AB and Stille AB.
Linus Byström has been employed as CEO of the company for seven years. During this time, the company has gone from being an exciting innovation company to having started to commercialize its products globally. The company has been listed on Nasdaq First North since last year. The company’s products are distributed through J&J MedTech and have now been launched in Japan. The American market is next in line.
“The board would like to thank Linus Byström for his impressive work during his seven years and wish him the best of luck in future challenges. Now that the company is entering the next phase, the board makes the assessment that new leadership with a focus on international sales and growth is needed,” says Yvonne Mårtensson, chairman of the board.
For additional information, please contact:
Yvonne Mårtensson, Chairman of the Board, [email protected]
Anders Hahn, Interim CEO, [email protected]
About Ortoma AB (publ)
Ortoma AB develops surgical systems for the planning and positioning of implants in hip, knee and spinal surgery. The purpose of the company’s surgical system, Ortoma Treatment Solution™ (OTS) is to enable surgeons to accurately measure and plan 3D surgery for the placement of joint implants, and during surgery, to optimally position the implant in the patient. Ortoma’s surgical system is aimed at providing better patient outcomes, fewer complications and less follow-up surgeries – and thus better long-term survival rates for implants. OTS is a system that is easily integrated into the processes and routines currently used in surgery, thereby increasing efficiency. Globally, more than 7.5 million orthopedic procedures are performed each year where OTS could be used in hip, knee and spinal surgery. In Sweden, around 42,000 surgical procedures were performed last year, involving hip, knee or spinal surgery. Ortoma’s B shares are listed on Nasdaq First North Growth Market Stockholm.